Michael Shetzline - Feb 28, 2022 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Role
CMO,SVP,Head-Res&Drug
Signature
/s/ Brian Tessler, Attorney-in-Fact
Stock symbol
IRWD
Transactions as of
Feb 28, 2022
Transactions value $
-$189,627
Form type
4
Date filed
3/2/2022, 03:01 PM
Previous filing
Jan 21, 2022
Next filing
Mar 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRWD Class A Common Stock Sale -$14.7K -1.37K -0.64% $10.77 212K Feb 28, 2022 Direct F1
transaction IRWD Class A Common Stock Sale -$31.4K -2.91K -1.38% $10.77 209K Feb 28, 2022 Direct F2
transaction IRWD Class A Common Stock Sale -$55.6K -5.16K -2.47% $10.77 204K Feb 28, 2022 Direct F3
transaction IRWD Class A Common Stock Sale -$41K -3.8K -1.87% $10.77 200K Feb 28, 2022 Direct F4
transaction IRWD Class A Common Stock Sale -$47K -4.36K -2.18% $10.77 195K Feb 28, 2022 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2019.
F2 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020.
F3 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting of the reporting person's performance-based restricted stock units granted on February 27, 2020.
F4 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting of the reporting person's performance-based restricted stock units granted on April 24, 2020
F5 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 22, 2021.